MARCIA MALONE: Open Payments
NPI 1740803022 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,282 in 52 payments from 17 companies in 2025. Trend: 2023 $1,666 · 2024 $1,234 · 2025 $1,282
Food & beverage: $1,282
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $334 |
| Corcept Therapeutics | 7 | $278 |
| AstraZeneca Pharmaceuticals LP | 6 | $163 |
| Otsuka America Pharmaceutical, Inc. | 4 | $78 |
| Astellas Pharma US Inc | 2 | $67 |
| Abbott Laboratories | 3 | $66 |
| Lilly USA, LLC | 3 | $51 |
| ABBVIE INC. | 2 | $46 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| Merck Sharp & Dohme LLC | 1 | $34 |
Products named: Korlym, Ozempic, FARXIGA, REXULTI, Veozah, FREESTYLE LIBRE 3, MOUNJARO, Wegovy.
Industry payments across NE — which companies pay providers there.
